Elsevier

Brain Research

Volume 580, Issues 1–2, 15 May 1992, Pages 35-43
Brain Research

The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model

https://doi.org/10.1016/0006-8993(92)90924-XGet rights and content

Abstract

The neuroprotective effects of NBQX, a selective antagonist for the AMPA/kainate subtype of excitatory amino acid receptors, were investigated in a rat focal ischaemia model, involving permanent occlusion of the left middle cerebral artery (MCA). NBQX (3, 10 or 30 mg/kg) was administered i.v. immediately after MCA occlusion and again 1 h later. The highest dose of NBQX (2 × 30mg/kg) gave significant protection against hemispheric (24%) and cortical (27%) ischaemic damage. The lower doses of NBQX (2 × 3or2 × 10mg/kg) were ineffective. No protection was seen against caudate damage for any of the doses of NBQX tested. NBQX has a t1/2 of 30 min, therefore, a second experiment was done in which a dose of 30 mg/kg was given as an i.v. bolus followed immediately by an infusion of 10 mg/kg/h for 4 h, dosing was started immediately after MCA occlusion. This dosing regimen resulted in a mean plasma level over the 4 h of 17 μg/ml, and significant protection against the volume of hemispheric (29%) and cortical (35%) ischaemic damage, which was slightly better than that achieved with two bolus doses of 30 mg/kg. Once again no protection was seen against caudate damage. We conclude that NBQX, an AMPA/kainate antagonist was neuroprotective in a focal ischaemia model in the rat.

References (47)

  • BlockG.A. et al.

    Excitatory amino acid receptor antagonists: failure to prevent ischemic neuronal damage

    J. Cereb. Blood Flow Metab.

    (1987)
  • BuchanA.

    Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted?

    Cerebrovasc. Brain Metab. Rev.

    (1990)
  • BuchanA. et al.

    The N-methyl-d-aspartate antagonist, MK-801, fails to protect against neuronal damage caused by transient, severe forebrain ischemia in adult rats

    J. Neurosci.

    (1991)
  • BullockR. et al.

    Focal cerebral ischaemia in the cat: pretreatment with a competitive NMDA receptor antagonist,d-CPPene

    J. Cereb. Blood Flow Metab.

    (1990)
  • ButcherS.P. et al.

    Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion

    Stroke

    (1990)
  • Diemer, N.H., Jörgensen, M.B., Sheardown, M. and Honoré, T., Effect of a new non-NMDA antagonist on cerebral ischemia...
  • GillR. et al.

    Systemic administration of MK-801 protects against ischaemia-induced hippocampal neurodegeneration in the gerbil

    J. Neurosci.

    (1987)
  • GillR. et al.

    Neuroprotective actions of MK-801 in a rat global ischaemia model

    J. Cereb. Blood Flow Metab.

    (1989)
    GillR. et al.

    Neuroprotective actions of MK-801 in a rat global ischaemia model

    J. Cereb. Blood Flow Metab.

    (1989)
  • GillR. et al.

    The neuroprotective action of Dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia

    Br. J. Pharmacol.

    (1991)
  • GillR. et al.

    The neuroprotective action of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model

  • GillR. et al.

    The neuroprotective action of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model

    J. Cereb. Blood Flow Metab.

    (1991)
  • HagbergH. et al.

    Ischaemia-induced shift of inhibitory and excitatory amino acids from intra- to extracellular compartments

    J. Cereb. Blood Flow Metab.

    (1985)
  • HatfieldR.H. et al.

    Triphenyltetrazolium chloride (TTC) as a marker for ischaemic changes in rat brain following permanent middle cerebral artery occlusion

    Neuropathol. Appl. Neurobiol.

    (1991)
  • Cited by (175)

    • Effects of AMPA receptor antagonist, NBQX, and extrasynaptic GABA <inf>A</inf> agonist, THIP, on social behavior of adolescent and adult rats

      2018, Physiology and Behavior
      Citation Excerpt :

      The design for Experiment 1 was a 2 age (adolescent; adult) × 2 sex (male; female) × 6 dose (0.0, 1.0, 2.0, 4.0, 6.0, 8.0 mg/kg NBQX) factorial with 10 animals per group (N = 240). The test doses of the selective AMPA receptor antagonist, NBQX disodium salt (2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt; Tocris Bioscience; half-life approximately 30 min [7,27] were dissolved in 0.9% sterile saline and delivered intraperitoneally (i.p.) at a volume of 2 ml/kg body weight, with control animals receiving an equivalent volume of saline. The design for Experiment 2 was a 2 age (adolescent; adult) × 2 sex (male; female) × 4 dose (0.0, 1.0, 2.0, 4.0 mg/kg THIP) factorial with 8–10 animals per group (N = 217).

    • The effect of AMPA receptor blockade on spatial information acquisition, consolidation and expression in juvenile rats

      2016, Neurobiology of Learning and Memory
      Citation Excerpt :

      The selective and competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAr) antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX disodium salt; Tocris) was dissolved in distilled water to concentrations of 5 mg/ml (13.15 mmol) and 10 mg/ml (26.29 mmol) and stored frozen. This drug readily crosses the blood-brain barrier (Gill, Nordholm, & Lodge, 1992) and has an in vivo half-life of approximately 15 min (Chizh, Cumberbatch, & Headley, 1994) making it valuable to study different phases of information processing in a juvenile rat where direct intracranial injection presents technical challenges. The 5 mg/kg NBQX dose is estimated to produce over 60% inhibition of AMPA-evoked spike activity in hippocampal neurons while the 10 mg/kg dose is estimated to produce over 80% inhibition of AMPA-evoked spike activity (Chizh et al., 1994; Mathiesen, Varming, & Jensen, 1998; Nielsen et al., 1999).

    View all citing articles on Scopus
    *

    Current address: Novo Nordisk A/S, CNS Division, Novo Nordisk Park, DK-2760 Malov, Denmark.

    View full text